Mirador Capital Partners LP acquired a new position in Horizon Therapeutics PLC (NASDAQ:HZNP) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 16,455 shares of the biopharmaceutical company’s stock, valued at approximately $596,000.
Other institutional investors have also recently modified their holdings of the company. IFP Advisors Inc raised its position in shares of Horizon Therapeutics by 163.0% in the fourth quarter. IFP Advisors Inc now owns 1,086 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 673 shares during the period. Quadrant Capital Group LLC purchased a new stake in shares of Horizon Therapeutics during the third quarter worth about $66,000. Tower Research Capital LLC TRC increased its stake in shares of Horizon Therapeutics by 384.1% during the second quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 2,689 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Horizon Therapeutics by 45.7% during the second quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 1,201 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Horizon Therapeutics during the second quarter worth about $125,000. Institutional investors and hedge funds own 88.24% of the company’s stock.
In other news, insider Jeff Kent sold 3,545 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $36.50, for a total value of $129,392.50. Following the completion of the sale, the insider now owns 121,988 shares of the company’s stock, valued at approximately $4,452,562. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Brian K. Beeler sold 12,475 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $30.02, for a total transaction of $374,499.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 126,888 shares of company stock valued at $4,413,598. 4.10% of the stock is owned by corporate insiders.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.14. Horizon Therapeutics had a net margin of 5.25% and a return on equity of 27.71%. The company had revenue of $335.50 million during the quarter, compared to analysts’ expectations of $330.60 million. During the same quarter in the prior year, the company earned $0.65 EPS. Horizon Therapeutics’s revenue was up 3.1% compared to the same quarter last year. Equities research analysts predict that Horizon Therapeutics PLC will post 1.55 earnings per share for the current fiscal year.
A number of analysts have recently commented on HZNP shares. Zacks Investment Research cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a research note on Tuesday, October 29th. Goldman Sachs Group started coverage on shares of Horizon Therapeutics in a research note on Wednesday, January 8th. They set a “neutral” rating and a $35.00 target price for the company. Piper Jaffray Companies reissued a “buy” rating and set a $49.00 target price (up previously from $36.00) on shares of Horizon Therapeutics in a research note on Tuesday, December 24th. BidaskClub raised shares of Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 28th. Finally, Jefferies Financial Group boosted their target price on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.14.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: What is the definition of a trade war?
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.